- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Starpharma Holdings Ltd (ASX:SPL)(PINK:SPHRY) today reported an important advance in its dendrimer-based drug-delivery program.
A Starpharma dendrimer combined with a widely-used cancer drug (doxorubicin) has achieved a significant extension of the drug's plasma half-life and a marked reduction in drug toxicity compared to administration of the drug alone. In this proof-of-concept animal study the efficacy of the dendrimer-drug construct was equivalent to that of the drug alone.
Doxorubicin was selected to illustrate the delivery technique because of its wide use as an anticancer agent, having application in Hodgkin's lymphoma, some leukemias, as well as cancers of the breast, lung, and ovaries. The clinical use of doxorubicin is often constrained by its cardiac toxicity which may result in congestive heart failure and dilated cardiomyopathy.
In Starpharma's recent study, an animal cancer-model ("xenograft") showed that Starpharma's dendrimer-doxorubicin construct (SPL8181) achieved the same inhibition of human breast-cancer tissue as doxorubicin alone, but with markedly reduced cardiac toxicity. Blinded histopathological examination of cardiac tissue samples from the dosed animals revealed significantly lower cardiotoxicity (p=0.019) in the dendrimer-doxorubicin construct treatment group (toxicity in 14% of samples) compared to a doxorubicin-only treatment group (toxicity in 86% of samples). Signs of reduced toxicity in other organs were also observed for the animals dosed with the dendrimer-based molecule compared to doxorubicin alone.
Starpharma's delivery technology works by attaching multiple drug molecules to the surface of a dendrimer nanoparticle. The result is that the dendrimer nanoparticle can target the drug to the tumour, in preference to other organs. This effect is illustrated for a second cancer molecule in Figure 3. Additionally Starpharma's proprietary dendrimer technology has been engineered to allow for the drug payload to be preferentially released from the nanoparticle in close proximity to the tumour.
Starpharma CEO, Dr Jackie Fairley said "Starpharma has already formed a number of partnerships based on its drug-delivery technology, including a dermal program with Stiefel Laboratories. The technology has application for both small molecule drugs and protein therapeutics and Starpharma is in advanced discussions with additional potential partners who have an interest in using it to improve the delivery, efficacy, and toxicity profile of their products."
The animal studies were conducted in collaboration with Associate Professor Chris Porter of the Victorian College of Pharmacy and Dr Carleen Cullinane of the Peter MacCallum Cancer Centre.
Starpharma has already taken a dendrimer-based drug into clinical trials conducted to US FDA requirements: VivaGel(R) vaginal microbicide is currently in Phase II clinical trials, and is the subject of a license agreement with Durex(R) condoms for use as a condom coating.
About Starpharma Holdings Ltd
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.
The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.
For more information, please click here
Dr Jackie Fairley
Chief Executive Officer
Copyright © Starpharma Holdings LimitedIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Chemical trickery corrals 'hyperactive' metal-oxide cluster December 8th, 2016
Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016
Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016